HLA Typing Market - Global Forecasts to 2030
商品番号 : SMB-33904
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年6月 |
| ページ数 | 267 |
| 図表数 | 308 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本レポートは、HLAタイピング市場を製品・サービス、技術、用途、エンドユーザー、地域の観点から分析しています。市場成長に影響を与える要因を網羅し、市場における様々な機会と課題を分析し、市場リーダーの競争環境の詳細を提供します。さらに、ミクロ市場を個々の成長傾向の観点から分析し、5つの主要地域（および各地域に属する国）における市場セグメントの収益予測も示しています。
The global HLA typing market is projected to grow from USD 1.7 billion in 2025 to USD 2.3 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.0% over the forecast period from 2025 to 2030. Transplantation continues to be the preferred treatment option for many patients suffering from chronic dialysis-dependent end-stage renal disease, as well as those requiring heart, liver, or bone marrow transplants. Over the past decade, significant advancements have been made in HLA typing technologies, antibody monitoring, diagnostic methods, and specialized software developed by various companies. These innovations have become integral to the organ transplantation process, enhancing precision and reliability, and have played a key role in driving the expansion of the HLA typing market.
世界のHLAタイピング市場は、2025年の17億米ドルから2030年には23億米ドルに成長すると予測されており、2025年から2030年の予測期間における年平均成長率（CAGR）は6.0%となる見込みです。移植は、慢性透析を必要とする末期腎疾患の患者、および心臓、肝臓、または骨髄移植を必要とする患者の多くにとって、依然として好ましい治療選択肢となっています。過去10年間で、HLAタイピング技術、抗体モニタリング、診断法、そして様々な企業によって開発された専用ソフトウェアにおいて、大きな進歩を遂げてきました。これらの革新は、臓器移植プロセスに不可欠なものとなり、精度と信頼性を高め、HLAタイピング市場の拡大を牽引する上で重要な役割を果たしてきました。
The commercial service providers segment accounted for the highest growth rate in the HLA typing market, by product and service, during the forecast period.
Based on end-user segmentation, the HLA (Human Leukocyte Antigen) typing market is categorized into commercial service providers, hospitals and transplant centers, and research laboratories and academic institutions. Among these, commercial service providers generated the highest revenue and are expected to witness strong growth, driven by the global rise in organ and stem cell transplants, which require precise, high-throughput HLA typing for effective donor-recipient matching. Growing awareness of personalized medicine, advancements in molecular diagnostics, and the increasing adoption of next-generation sequencing (NGS) technologies are key factors fueling demand for more specialized reagents and kits.
The diagnostic applications segment held the largest market share in 2024.
The HLA typing market is categorized based on application into diagnostic applications—including donor-recipient cross-matching, infectious disease testing, cancer diagnosis and prevention, transfusion therapy, and other diagnostic uses—and research applications. The diagnostic application segment is projected to dominate the market throughout the forecast period, with infectious disease testing accounting for the largest share within this segment. This is largely due to the heightened risk transplant recipients face of acquiring infections from donors. Current donor epidemiological screening methods and laboratory diagnostics have limitations in accurately assessing these risks, making infectious disease testing a critical and continuously growing focus area within the diagnostic segment of the transplant diagnostics market.
The market in the North America region is expected to hold a significant market share for the HLA typing market in 2023.
The HLA typing market spans five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In North America, the market is experiencing strong growth driven by the increasing demand for organ and stem cell transplants, the rising prevalence of chronic and autoimmune diseases, and the adoption of advanced molecular diagnostic techniques. This growth is further supported by a well-established healthcare infrastructure, government initiatives such as the National Marrow Donor Program, and greater public awareness of the importance of accurate HLA matching. The region is a hub for innovation and research, with many leading companies in the HLA typing space headquartered in the region. As a result, cutting-edge technologies, including next-generation sequencing (NGS), are being rapidly adopted, further fueling market expansion.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side: 60% and Demand Side: 40%
- By Designation: Managers: 20%, CXOs & Directors: 30%, and Executives: 50%
- By Region: North America: 40%, Europe: 30%, Asia Pacific: 20%, Latin America: 5%, and Middle East & Africa: 5%
List of Key Companies Profiled in the Report
The prominent players in the HLA typing market are Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), F. Hoffman-La Roche Ltd (Switzerland), Accelerate Diagnostics, Inc. (US), Alpha Biotech Limited (Israel), Bag Diagnostics GmbH (Germany), Caredx, Inc. (US), Creative Biolabs (US), Fujirebio Holdings Inc (Japan), Gendx (Netherlands), Hologic, Inc. (US), Histogenetics LLC (US), Hansa Biopharma AB (Sweden), Illumina, Inc. (US), Inno-Train Diagnostik GmbH (Germany), Immucor, Inc. (US), Krishgen Biosystems (India), Omixon Inc. (Hungary), PacBio (US), Proimmune Ltd (UK), Pacific Bioscience of California Inc. (US), TBG Diagnostics Limited (Australia), and Takara Bio Inc. (Japan), among others.
Research Coverage
This report studies the HLA typing market based on product & service, technology, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to buy this report
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall HLA typing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (growing number of organ transplantation procedures, rising technological advancements in HLA typing, increasing funding for research activities, growing prevalence of infectious diseases), restraints (high cost of HLA typing products, limited reimbursements for target procedures), opportunities (rising adoption of cross-matching and chimerism testing procedures, growing awareness of organ donations), and challenges (limited number of organ donations and long waiting lists for transplantations, shortage of skilled professionals)
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals/launches in the HLA typing market
- Market Development: Comprehensive information about lucrative markets
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the HLA typing market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the HLA typing market.
Table of Contents
1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.3 STUDY SCOPE 27
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 27
1.3.2 INCLUSIONS AND EXCLUSIONS 28
1.3.3 YEARS CONSIDERED 28
1.4 CURRENCY CONSIDERED 28
1.5 STAKEHOLDERS 29
1.6 SUMMARY OF CHANGES 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
2.1.1 SECONDARY DATA 31
2.1.1.1 Indicative list of secondary sources 32
2.1.1.2 Key data from secondary sources 32
2.1.2 PRIMARY DATA 33
2.1.2.1 Primary sources 33
2.1.2.2 Key data from primary sources 34
2.1.2.3 Key industry insights 34
2.1.2.4 Breakdown of primary interviews 35
2.2 MARKET SIZE ESTIMATION 35
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 37
2.2.2 END-USER-BASED MAPPING MARKET ESTIMATION 38
2.3 GROWTH FORECASTING MODEL 39
2.4 DATA TRIANGULATION AND MARKET BREAKDOWN 41
2.5 RESEARCH ASSUMPTIONS 42
2.6 RESEARCH LIMITATIONS 42
2.7 RISK ANALYSIS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 48
4.1 HLA TYPING MARKET OVERVIEW 48
4.2 REGIONAL SNAPSHOT OF HLA TYPING MARKET 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
5.2.1 DRIVERS 51
5.2.1.1 Rising number of organ transplantation procedures 51
5.2.1.2 Increasing technological advancements in sanger sequencing 52
5.2.1.3 Growing funding and research activities 52
5.2.1.4 Increasing prevalence of infectious and autoimmune diseases 53
5.2.2 RESTRAINTS 53
5.2.2.1 High cost of hla typing products 53
5.2.2.2 Limited reimbursement policies 54
5.2.3 OPPORTUNITIES 54
5.2.3.1 Adoption of cross-matching and chimerism testing 54
5.2.3.2 Growth opportunities in emerging markets 55
5.2.4 CHALLENGES 55
5.2.4.1 Shortage of skilled professionals 55
5.2.4.2 Lack of standardization across laboratories 56
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 56
5.4 PRICING ANALYSIS 57
5.4.1 AVERAGE SELLING PRICE, BY INSTRUMENTS 57
5.4.2 AVERAGE SELLING PRICE, BY REAGENTS 58
5.4.3 AVERAGE SELLING PRICE OF KEY PLAYERS, BY INSTRUMENTS 58
5.4.4 AVERAGE SELLING PRICE TREND, BY REGION 59
5.5 VALUE CHAIN ANALYSIS 60
5.5.1 R&D 60
5.5.2 RAW MATERIAL PROCUREMENT & PRODUCT DEVELOPMENT 60
5.5.3 MARKETING, SALES, AND DISTRIBUTION 60
5.5.4 POST-SALES SERVICES 61
5.6 SUPPLY CHAIN ANALYSIS 61
5.6.1 PROMINENT COMPANIES 61
5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES 61
5.6.3 END USERS 62
5.7 ECOSYSTEM ANALYSIS 62
5.8 INVESTMENT AND FUNDING SCENARIO 63
5.9 TECHNOLOGY ANALYSIS 64
5.9.1 KEY TECHNOLOGIES 65
5.9.1.1 Sequence-based typing 65
5.9.1.2 Next-generation sequencing 65
5.9.2 COMPLEMENTARY TECHNOLOGIES 65
5.9.2.1 Sample preparation & dna extraction technologies 65
5.9.2.2 Bioinformatics and data analysis software 66
5.9.3 ADJACENT TECHNOLOGIES 66
5.9.3.1 Transplant diagnostics 66
5.10 PATENT ANALYSIS 66
5.11 TRADE ANALYSIS 68
5.11.1 IMPORT SCENARIO (HS CODE 3822) 68
5.11.2 EXPORT SCENARIO (HS CODE 3822) 70
5.12 KEY CONFERENCES AND EVENTS, 2025–2026 71
5.13 CASE STUDY ANALYSIS 71
5.14 REGULATORY LANDSCAPE 73
5.14.1 REGULATORY GUIDELINES 73
5.14.1.1 North America 73
5.14.1.1.1 US 73
5.14.1.1.2 Canada 73
5.14.1.2 Europe 73
5.14.1.2.1 UK 73
5.14.1.2.2 France 73
5.14.1.2.3 Germany 74
5.14.1.3 Asia pacific 74
5.14.1.3.1 China 74
5.14.1.3.2 Japan 74
5.14.1.3.3 India 74
5.14.1.4 Latin America 74
5.14.1.4.1 Brazil 74
5.14.1.4.2 Mexico 75
5.14.1.5 Middle East & Africa 75
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
5.15 PORTER’S FIVE FORCE ANALYSIS 76
5.15.1 BARGAINING POWER OF SUPPLIERS 78
5.15.2 BARGAINING POWER OF BUYERS 78
5.15.3 THREAT OF NEW ENTRANTS 78
5.15.4 THREAT OF SUBSTITUTES 78
5.15.5 INTENSITY OF COMPETITIVE RIVALRY 78
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 79
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
5.16.2 KEY BUYING CRITERIA 80
5.17 UNMET NEEDS 81
5.18 IMPACT OF AI ON HLA TYPING MARKET 81
5.18.1 INTRODUCTION 81
5.18.2 MARKET POTENTIAL OF HLA TYPING PRODUCTS FOR PRE TRANSPLANT EVALUATION 82
5.18.3 AI USE CASES 82
5.18.4 KEY COMPANIES IMPLEMENTING AI 82
5.19 IMPACT OF 2025 US TARIFF 83
5.19.1 INTRODUCTION 83
5.19.2 KEY TARIFF RATES 83
5.19.3 PRICE IMPACT ANALYSIS 84
5.19.4 IMPACT ON COUNTRY/REGION 84
5.19.4.1 Us 84
5.19.4.2 Europe 84
5.19.4.3 Asia pacific 84
5.19.5 IMPACT ON END-USE INDUSTRIES 85
6 HLA TYPING MARKET, BY PRODUCT & SERVICE 86
6.1 INTRODUCTION 87
6.2 REAGENTS & CONSUMABLES 87
6.2.1 INCREASED DEMAND FOR SPECIALIZED CONSUMABLES TO DRIVE MARKET 87
6.3 INSTRUMENTS 88
6.3.1 NEED FOR DONOR-RECIPIENT MATCHING AND IMMUNOGENETIC RESEARCH TO AID GROWTH 88
6.4 SOFTWARE & SERVICES 89
6.4.1 GROWING DEMAND FOR ADVANCED AND USER-FRIENDLY SOFTWARE TO BOOST MARKET 89
7 HLA TYPING MARKET, BY TECHNOLOGY 91
7.1 INTRODUCTION 92
7.2 MOLECULAR ASSAY TECHNOLOGIES 92
7.2.1 PCR-BASED MOLECULAR ASSAYS 93
7.2.1.1 Sequence-specific primer-PCR 94
7.2.1.1.1 Higher speed, precision, and affordability to favor growth 94
7.2.1.2 Sequence-specific oligonucleotide-PCR 95
7.2.1.2.1 Growing applications of PCR in donor-recipient matching, cancer, rheumatoid, and arthritis to drive market 95
7.2.1.3 Real-time PCR 96
7.2.1.3.1 Increasing preference for genome-based molecular diagnostics to facilitate growth 96
7.2.1.4 Other PCR-based molecular assays 97
7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS 98
7.2.2.1 Sanger sequencing 99
7.2.2.1.1 Increasing use of sanger sequencing in clinical settings for organ and bone marrow transplantations to aid growth 99
7.2.2.2 Next-generation sequencing 100
7.2.2.2.1 Growing reliance on outsourcing to fuel market 100
7.2.2.3 Other sequencing-based molecular assays 101
7.3 NON-MOLECULAR ASSAY TECHNOLOGIES 102
7.3.1 RISING IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO AUGMENT GROWTH 102
8 HLA TYPING MARKET, BY APPLICATION 104
8.1 INTRODUCTION 105
8.2 DIAGNOSTIC APPLICATIONS 105
8.2.1 DONOR-RECIPIENT CROSS-MATCHING 106
8.2.1.1 Increasing focus on successful organ transplants to foster growth 106
8.2.2 INFECTIOUS DISEASE TESTING 107
8.2.2.1 Rising prevalence of infectious diseases to accelerate growth 107
8.2.3 CANCER DIAGNOSTIC & PREVENTION 108
8.2.3.1 Increasing demand for accurate and early cancer diagnosis to bolster growth 108
8.2.4 TRANSFUSION THERAPY 109
8.2.4.1 Growing clinical evidence supporting hla typing to propel market 109
8.2.5 OTHER DIAGNOSTIC APPLICATIONS 110
8.3 RESEARCH APPLICATIONS 111
8.3.1 EXPANDING USE OF GENOMIC TECHNOLOGIES TO EXPEDITE GROWTH 111
9 HLA TYPING MARKET, BY END USER 113
9.1 INTRODUCTION 114
9.2 COMMERCIAL SERVICE PROVIDERS 114
9.2.1 RISING DEMAND FOR OUTSOURCED SERVICES TO CONTRIBUTE TO GROWTH 114
9.3 HOSPITALS & TRANSPLANT CENTERS 115
9.3.1 GROWING DEMAND FOR ORGAN TRANSPLANTS TO BOOST MARKET 115
9.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 116
9.4.1 INCREASING RESEARCH ACTIVITIES TO PROMOTE GROWTH 116
10 HLA TYPING MARKET, BY REGION 118
10.1 INTRODUCTION 119
10.2 NORTH AMERICA 120
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 120
10.2.2 US 124
10.2.2.1 Expanding donor registries and precision medicine to propel market 124
10.2.3 CANADA 126
10.2.3.1 Evolving healthcare landscape to augment growth 126
10.3 EUROPE 128
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 129
10.3.2 GERMANY 133
10.3.2.1 Growing investments in genomic research and digital healthcare to drive market 133
10.3.3 UK 135
10.3.3.1 Strong healthcare infrastructure and centrally coordinated transplant system to foster growth 135
10.3.4 FRANCE 137
10.3.4.1 Growing adoption for donor-recipient compatibility testing to boost market 137
10.3.5 SPAIN 140
10.3.5.1 Increasing solid organ transplantation procedures to facilitate growth 140
10.3.6 ITALY 142
10.3.6.1 Supportive government policies and strong healthcare infrastructure to promote growth 142
10.3.7 REST OF EUROPE 144
10.4 ASIA PACIFIC 145
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 147
10.4.2 CHINA 151
10.4.2.1 Increasing utilization of hla typing for donor-recipient matching to propel market 151
10.4.3 JAPAN 153
10.4.3.1 Growing burden of chronic diseases to boost market 153
10.4.4 INDIA 155
10.4.4.1 Increasing government efforts to offer free access to support growth 155
10.4.5 SOUTH KOREA 157
10.4.5.1 Advanced healthcare to contribute to growth 157
10.4.6 AUSTRALIA 159
10.4.6.1 Increasing integration of genomic tools in diagnostics to promote growth 159
10.4.7 REST OF ASIA PACIFIC 161
10.5 LATIN AMERICA 163
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 163
10.5.2 BRAZIL 167
10.5.2.1 Growing adoption of next-generation sequencing to drive market 167
10.5.3 MEXICO 169
10.5.3.1 Supportive business environment to bolster growth 169
10.5.4 REST OF LATIN AMERICA 171
10.6 MIDDLE EAST & AFRICA 173
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 173
10.6.2 GCC COUNTRIES 177
10.6.2.1 Improvements in healthcare infrastructure to spur growth 177
10.6.3 REST OF MIDDLE EAST & AFRICA 179
11 COMPETITIVE LANDSCAPE 182
11.1 INTRODUCTION 182
11.2 KEY PLAYER STRATEGIES 182
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HLA TYPING MARKET 182
11.3 REVENUE ANALYSIS, 2020–2024 183
11.4 MARKET SHARE ANALYSIS, 2024 184
11.5 COMPANY VALUATION AND FINANCIAL METRICS 188
11.6 PRODUCT/BRAND COMPARISON 189
11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 190
11.7.1 STARS 190
11.7.2 EMERGING LEADERS 190
11.7.3 PERVASIVE PLAYERS 190
11.7.4 PARTICIPANTS 190
11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 192
11.7.5.1 Company footprint 192
11.7.5.2 Region footprint 193
11.7.5.3 Product footprint 194
11.7.5.4 Technology footprint 195
11.7.5.5 Application footprint 196
11.7.5.6 End-user footprint 197
11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 198
11.8.1 PROGRESSIVE COMPANIES 198
11.8.2 RESPONSIVE COMPANIES 198
11.8.3 DYNAMIC COMPANIES 198
11.8.4 STARTING BLOCKS 198
11.8.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2024 200
11.8.5.1 Detailed list of key startup/sme players 200
11.8.5.2 Competitive benchmarking of startups/smes 201
11.9 COMPETITIVE SCENARIO 201
11.9.1 PRODUCT LAUNCHES AND APPROVALS 201
11.9.2 DEALS 203
11.9.3 EXPANSIONS 205
12 COMPANY PROFILES 206
12.1 MAJOR PLAYER 206
12.1.1 BD 206
12.1.1.1 Business overview 206
12.1.1.2 Products offered 207
12.1.1.3 Mnm view 208
12.1.1.3.1 Key Strengths 208
12.1.1.3.2 Strategic choices 208
12.1.1.3.3 Weaknesses and competitive threats 208
12.1.2 THERMO FISHER SCIENTIFIC INC. 209
12.1.2.1 Business overview 209
12.1.2.2 Products offered 210
12.1.2.3 Recent developments 211
12.1.2.3.1 Product launches and approvals 211
12.1.2.3.2 Deals 212
12.1.2.3.3 Expansions 212
12.1.2.4 Mnm view 213
12.1.2.4.1 Key strengths 213
12.1.2.4.2 Strategic choices 213
12.1.2.4.3 Weaknesses and competitive threats 213
12.1.3 ILLUMINA, INC. 214
12.1.3.1 Business overview 214
12.1.3.2 Products offered 215
12.1.3.3 Recent developments 216
12.1.3.3.1 Expansions 216
12.1.3.4 Mnm view 216
12.1.3.4.1 Key strengths 216
12.1.3.4.2 Strategic choices 216
12.1.3.4.3 Weaknesses and competitive threats 217
12.1.4 QIAGEN 218
12.1.4.1 Business overview 218
12.1.4.2 Products offered 219
12.1.4.3 Recent developments 221
12.1.4.3.1 Product launches and approvals 221
12.1.4.3.2 Deals 222
12.1.4.4 Mnm view 222
12.1.4.4.1 Key strengths 222
12.1.4.4.2 Strategic choices 222
12.1.4.4.3 Weaknesses and competitive threats 222
12.1.5 BIO-RAD LABORATORIES, INC. 223
12.1.5.1 Business overview 223
12.1.5.2 Products offered 224
12.1.5.3 Recent developments 226
12.1.5.3.1 Product launches and approvals 226
12.1.5.4 Mnm view 226
12.1.5.4.1 Key strengths 226
12.1.5.4.2 Strategic choices 226
12.1.5.4.3 Weaknesses and competitive threats 226
12.1.6 F. HOFFMANN-LA ROCHE LTD 227
12.1.6.1 Business overview 227
12.1.6.2 Products offered 228
12.1.6.3 Recent developments 229
12.1.6.3.1 Product launches and approvals 229
12.1.6.3.2 Expansions 229
12.1.6.4 Mnm view 230
12.1.6.4.1 Key strengths 230
12.1.6.4.2 Strategic choices 230
12.1.6.4.3 Weaknesses and competitive threats 230
12.1.7 CAREDX, INC. 231
12.1.7.1 Business overview 231
12.1.7.2 Products offered 232
12.1.7.3 Recent developments 232
12.1.7.3.1 Product launches and approvals 232
12.1.7.3.2 Deals 233
12.1.8 WERFEN 234
12.1.8.1 Business overview 234
12.1.8.2 Products offered 234
12.1.8.3 Recent developments 235
12.1.8.3.1 Product launches and approvals 235
12.1.8.3.2 Deals 235
12.1.9 DIASORIN S.P.A. 236
12.1.9.1 Business overview 236
12.1.9.2 Products offered 237
12.1.9.3 Recent developments 237
12.1.9.3.1 Product launches and approvals 237
12.1.10 TBG BIOTECHNOLOGY CORPORATION 238
12.1.10.1 Business overview 238
12.1.10.2 Products offered 238
12.1.10.3 Recent developments 239
12.1.10.3.1 Product launches and approvals 239
12.1.10.3.2 Deals 239
12.1.11 FUJIREBIO 240
12.1.11.1 Business overview 240
12.1.11.2 Products offered 240
12.1.11.3 Recent developments 241
12.1.11.3.1 Deals 241
12.1.12 EUROBIO SCIENTIFIC 242
12.1.12.1 Business overview 242
12.1.12.2 Products offered 243
12.1.12.3 Recent developments 243
12.1.12.3.1 Product launches and approvals 243
12.1.12.3.2 Deals 244
12.1.13 PACBIO 245
12.1.13.1 Business overview 245
12.1.13.2 Products offered 246
12.1.13.3 Recent developments 247
12.1.13.3.1 Product launches and approvals 247
12.1.13.3.2 Deals 247
12.1.14 BAG DIAGNOSTICS GMBH 248
12.1.14.1 Business overview 248
12.1.14.2 Products offered 248
12.1.15 CREATIVE BIOLABS 249
12.1.15.1 Business overview 249
12.1.15.2 Products offered 249
12.2 OTHER PLAYERS 250
12.2.1 HISTOGENETICS LLC 250
12.2.2 SCISCO GENETICS, INC. 251
12.2.3 INNO-TRAIN DIAGNOSTIK GMBH 252
12.2.4 BIONOBIS 253
12.2.5 TAKARA BIO INC. 254
12.2.6 KRISHGEN BIOSYSTEMS 255
12.2.7 SCIENCELL RESEARCH LABORATORIES, INC. 256
12.2.8 PROIMMUNE LTD. 257
12.2.9 BIOFORTUNA LIMITED 258
12.2.10 ALPHA BIOTECH LIMITED 259
13 APPENDIX 260
13.1 DISCUSSION GUIDE 260
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 263
13.3 CUSTOMIZATION OPTIONS 265
13.4 RELATED REPORTS 265
13.5 AUTHOR DETAILS 266
LIST OF TABLES
TABLE 1 HLA TYPING MARKET: INCLUSIONS AND EXCLUSIONS 28
TABLE 2 HLA TYPING MARKET: RISK ANALYSIS 43
TABLE 3 HLA TYPING MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 51
TABLE 4 AVERAGE SELLING PRICE OF KEY PLAYERS, BY INSTRUMENTS, 2024 (USD) 58
TABLE 5 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022–2024 59
TABLE 6 HLA TYPING MARKET: ROLE OF COMPANIES IN ECOSYSTEM 62
TABLE 7 HLA TYPING MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2024–2025 68
TABLE 8 IMPORT SCENARIO FOR HS CODE 3822, BY COUNTRY,
2020–2024 (USD THOUSAND) 69
TABLE 9 EXPORT SCENARIO FOR HS CODE 3822, BY COUNTRY,
2020–2024 (USD THOUSAND) 70
TABLE 10 HLA TYPING MARKET KEY CONFERENCES AND EVENTS, 2025–2026 71
TABLE 11 DEVELOPMENT AND IMPLEMENTATION OF INFORMATION SYSTEM FOR
HLA TYPING LABORATORY MANAGEMENT 71
TABLE 12 IMPROVED HLA TYPING ACCURACY ACROSS DIVERSE SAMPLE TYPES USING SEQUENCING-BASED ASSAYS 72
TABLE 13 HIGH-RESOLUTION EXTENDED 6-LOCI HLA TYPING FOR IDENTIFYING
RELATED DONORS IN INDIAN SUBCONTINENT 72
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 75
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 75
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 76
TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 18 HLA TYPING MARKET: PORTER’S FIVE FORCES ANALYSIS 77
TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS,
BY PRODUCT & SERVICE (%) 79
TABLE 20 KEY BUYING CRITERIA FOR END USERS 80
TABLE 21 HLA TYPING MARKET: UNMET NEEDS 81
TABLE 22 US ADJUSTED RECIPROCAL TARIFF RATES 83
TABLE 23 HLA TYPING MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 87
TABLE 24 HLA TYPING MARKET FOR REAGENTS & CONSUMABLES, BY REGION,
2023–2030 (USD MILLION) 88
TABLE 25 HLA TYPING MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION) 89
TABLE 26 HLA TYPING MARKET FOR SOFTWARE & SERVICES, BY REGION,
2023–2030 (USD MILLION) 90
TABLE 27 HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 92
TABLE 28 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES,
BY TYPE, 2023–2030 (USD MILLION) 93
TABLE 29 HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES,
BY REGION, 2023–2030 (USD MILLION) 93
TABLE 30 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 94
TABLE 31 HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY REGION, 2023–2030 (USD MILLION) 94
TABLE 32 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR MARKET,
BY REGION, 2023–2030 (USD MILLION) 95
TABLE 33 HLA TYPING MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2023–2030 (USD MILLION) 96
TABLE 34 HLA TYPING MARKET FOR REAL-TIME PCR, BY REGION,
2023–2030 (USD MILLION) 97
TABLE 35 HLA TYPING MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS,
BY REGION, 2023–2030 (USD MILLION) 98
TABLE 36 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 99
TABLE 37 HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2023–2030 (USD MILLION) 99
TABLE 38 HLA TYPING MARKET FOR SANGER SEQUENCING, BY REGION,
2023–2030 (USD MILLION) 100
TABLE 39 HLA TYPING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION,
2023–2030 (USD MILLION) 101
TABLE 40 HLA TYPING MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS,
BY REGION, 2023–2030 (USD MILLION) 102
TABLE 41 HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES,
BY REGION, 2023–2030 (USD MILLION) 103
TABLE 42 HLA TYPING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 105
TABLE 43 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 106
TABLE 44 HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION,
2023–2030 (USD MILLION) 106
TABLE 45 HLA TYPING MARKET FOR DONOR-RECIPIENT CROSS-MATCHING, BY REGION, 2023–2030 (USD MILLION) 107
TABLE 46 HLA TYPING MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION,
2023–2030 (USD MILLION) 108
TABLE 47 HLA TYPING MARKET FOR CANCER DIAGNOSIS & PREVENTION, BY REGION,
2023–2030 (USD MILLION) 109
TABLE 48 HLA TYPING MARKET FOR TRANSFUSION THERAPY, BY REGION,
2023–2030 (USD MILLION) 110
TABLE 49 HLA TYPING MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION,
2023–2030 (USD MILLION) 111
TABLE 50 HLA TYPING MARKET FOR RESEARCH APPLICATIONS, BY REGION,
2023–2030 (USD MILLION) 112
TABLE 51 HLA TYPING MARKET, BY END USER, 2023–2030 (USD MILLION) 114
TABLE 52 HLA TYPING MARKET FOR COMMERCIAL SERVICE PROVIDERS, BY REGION,
2023–2030 (USD MILLION) 115
TABLE 53 HLA TYPING MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2023–2030 (USD MILLION) 116
TABLE 54 HLA TYPING MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES,
BY REGION, 2023–2030 (USD MILLION) 117
TABLE 55 HLA TYPING FOR TRANSPLANT MARKET: TRANSPLANT VOLUME BY TYPE, 2023 (NUMBER OF TRANSPLANTS) 119
TABLE 56 NORTH AMERICA: TRANSPLANT VOLUME, 2024 120
TABLE 57 NORTH AMERICA: HLA TYPING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 58 NORTH AMERICA: HLA TYPING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 122
TABLE 59 NORTH AMERICA: HLA TYPING MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 122
TABLE 60 NORTH AMERICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 122
TABLE 61 NORTH AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 123
TABLE 62 NORTH AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 123
TABLE 63 NORTH AMERICA: HLA TYPING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 123
TABLE 64 NORTH AMERICA: HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 124
TABLE 65 NORTH AMERICA: HLA TYPING MARKET, BY END USER,
2023–2030 (USD MILLION) 124
TABLE 66 US: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 125
TABLE 67 US: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 125
TABLE 68 US: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE,
2023–2030 (USD MILLION) 126
TABLE 69 US: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 126
TABLE 70 CANADA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 127
TABLE 71 CANADA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 127
TABLE 72 CANADA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 128
TABLE 73 CANADA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 128
TABLE 74 EUROPE: TRANSPLANT VOLUME, 2024 129
TABLE 75 EUROPE: HLA TYPING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 76 EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 130
TABLE 77 EUROPE: HLA TYPING MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 130
TABLE 78 EUROPE: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES,
BY TYPE, 2023–2030 (USD MILLION) 131
TABLE 79 EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 131
TABLE 80 EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 132
TABLE 81 EUROPE: HLA TYPING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 132
TABLE 82 EUROPE: HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 133
TABLE 83 EUROPE: HLA TYPING MARKET, BY END USER, 2023–2030 (USD MILLION) 133
TABLE 84 GERMANY: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 134
TABLE 85 GERMANY: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES,
BY TYPE, 2023–2030 (USD MILLION) 134
TABLE 86 GERMANY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 135
TABLE 87 GERMANY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 135
TABLE 88 UK: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 136
TABLE 89 UK: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 136
TABLE 90 UK: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE,
2023–2030 (USD MILLION) 137
TABLE 91 UK: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 137
TABLE 92 FRANCE: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 138
TABLE 93 FRANCE: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 138
TABLE 94 FRANCE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 139
TABLE 95 FRANCE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 139
TABLE 96 SPAIN: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 140
TABLE 97 SPAIN: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 140
TABLE 98 SPAIN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 141
TABLE 99 SPAIN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 141
TABLE 100 ITALY: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 142
TABLE 101 ITALY: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES,
BY TYPE, 2023–2030 (USD MILLION) 142
TABLE 102 ITALY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 143
TABLE 103 ITALY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 143
TABLE 104 REST OF EUROPE: HLA TYPING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 144
TABLE 105 REST OF EUROPE: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 144
TABLE 106 REST OF EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 145
TABLE 107 REST OF EUROPE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 145
TABLE 108 ASIA PACIFIC: TRANSPLANT VOLUME, 2024 147
TABLE 109 ASIA PACIFIC: HLA TYPING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 110 ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 148
TABLE 111 ASIA PACIFIC: HLA TYPING MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 148
TABLE 112 ASIA PACIFIC: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES,
BY TYPE, 2023–2030 (USD MILLION) 149
TABLE 113 ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED ASSAY TECHNOLOGIES,
BY TYPE, 2023–2030 (USD MILLION) 149
TABLE 114 ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 150
TABLE 115 ASIA PACIFIC: HLA TYPING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 150
TABLE 116 ASIA PACIFIC: HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 150
TABLE 117 ASIA PACIFIC: HLA TYPING MARKET, BY END USER, 2023–2030 (USD MILLION) 151
TABLE 118 CHINA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 152
TABLE 119 CHINA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 152
TABLE 120 CHINA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 152
TABLE 121 CHINA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 153
TABLE 122 JAPAN: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 154
TABLE 123 JAPAN: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 124 JAPAN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 125 JAPAN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 155
TABLE 126 INDIA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 156
TABLE 127 INDIA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 156
TABLE 128 INDIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 156
TABLE 129 INDIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 157
TABLE 130 SOUTH KOREA: HLA TYPING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 157
TABLE 131 SOUTH KOREA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES,
BY TYPE, 2023–2030 (USD MILLION) 158
TABLE 132 SOUTH KOREA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 158
TABLE 133 SOUTH KOREA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 159
TABLE 134 AUSTRALIA: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 160
TABLE 135 AUSTRALIA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES,
BY TYPE, 2023–2030 (USD MILLION) 160
TABLE 136 AUSTRALIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 160
TABLE 137 AUSTRALIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 161
TABLE 138 REST OF ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 161
TABLE 139 REST OF ASIA PACIFIC: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 162
TABLE 140 REST OF ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 162
TABLE 141 REST OF ASIA PACIFIC: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 162
TABLE 142 LATIN AMERICA: TRANSPLANT VOLUME, 2024 164
TABLE 143 LATIN AMERICA: HLA TYPING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 144 LATIN AMERICA: HLA TYPING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 164
TABLE 145 LATIN AMERICA: HLA TYPING MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 165
TABLE 146 LATIN AMERICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES,
BY TYPE, 2023–2030 (USD MILLION) 165
TABLE 147 LATIN AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 165
TABLE 148 LATIN AMERICA: HLA TYPING MARKET FOR PCR-BASED ASSAY TECHNOLOGIES,
BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 149 LATIN AMERICA: HLA TYPING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 166
TABLE 150 LATIN AMERICA: HLA TYPING MARKET, BY DIAGNOSTIC APPLICATION,
2023–2030 (USD MILLION) 166
TABLE 151 LATIN AMERICA: HLA TYPING MARKET, BY END USER, 2023–2030 (USD MILLION) 167
TABLE 152 BRAZIL: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 168
TABLE 153 BRAZIL: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES,
BY TYPE, 2023–2030 (USD MILLION) 168
TABLE 154 BRAZIL: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 168
TABLE 155 BRAZIL: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 169
TABLE 156 MEXICO: HLA TYPING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 170
TABLE 157 MEXICO: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 170
TABLE 158 MEXICO: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 170
TABLE 159 MEXICO: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 171
TABLE 160 REST OF LATIN AMERICA: HLA TYPING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 171
TABLE 161 REST OF LATIN AMERICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 172
TABLE 162 REST OF LATIN AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 172
TABLE 163 REST OF LATIN AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 172
TABLE 164 MIDDLE EAST & AFRICA: TRANSPLANT VOLUME, 2024 173
TABLE 165 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY REGION,
2023–2030 (USD MILLION) 174
TABLE 166 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 174
TABLE 167 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 174
TABLE 168 MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 169 MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 170 MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 175
TABLE 171 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 176
TABLE 172 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY DIAGNOSTIC APPLICATION, 2023–2030 (USD MILLION) 176
TABLE 173 MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY END USER,
2023–2030 (USD MILLION) 177
TABLE 174 GCC COUNTRIES: HLA TYPING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 177
TABLE 175 GCC COUNTRIES: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 178
TABLE 176 GCC COUNTRIES: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS,
BY TYPE, 2023–2030 (USD MILLION) 178
TABLE 177 GCC COUNTRIES: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 179
TABLE 178 REST OF MIDDLE EAST & AFRICA: HLA TYPING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 179
TABLE 179 REST OF MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 180
TABLE 180 REST OF MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 180
TABLE 181 REST OF MIDDLE EAST & AFRICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 182 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
IN HLA TYPING MARKET 182
TABLE 183 HLA TYPING MARKET: DEGREE OF COMPETITION 186
TABLE 184 HLA TYPING MARKET: REGION FOOTPRINT 193
TABLE 185 HLA TYPING MARKET: PRODUCT & SERVICE FOOTPRINT 194
TABLE 186 HLA TYPING MARKET: TECHNOLOGY FOOTPRINT 195
TABLE 187 HLA TYPING MARKET: APPLICATION FOOTPRINT 196
TABLE 188 HLA TYPING MARKET: END-USER FOOTPRINT 197
TABLE 189 HLA TYPING MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 200
TABLE 190 HLA TYPING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 201
TABLE 191 HLA TYPING MARKET: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–APRIL 2025 202
TABLE 192 HLA TYPING MARKET: DEALS, JANUARY 2021–APRIL 2025 203
TABLE 193 HLA TYPING MARKET: EXPANSIONS, JANUARY 2021–APRIL 2025 205
TABLE 194 BD: COMPANY OVERVIEW 206
TABLE 195 BD: PRODUCTS OFFERED 207
TABLE 196 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW 209
TABLE 197 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 210
TABLE 198 THERMO FISHER SCIENTIFIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 211
TABLE 199 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–APRIL 2025 212
TABLE 200 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–APRIL 2025 212
TABLE 201 ILLUMINA, INC.: COMPANY OVERVIEW 214
TABLE 202 ILLUMINA, INC.: PRODUCTS OFFERED 215
TABLE 203 ILLUMINA, INC.: EXPANSIONS, JANUARY 2021–APRIL 2025 216
TABLE 204 QIAGEN: COMPANY OVERVIEW 218
TABLE 205 QIAGEN: PRODUCTS OFFERED 219
TABLE 206 QIAGEN: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–APRIL 2025 221
TABLE 207 QIAGEN: DEALS, JANUARY 2021–APRIL 2025 222
TABLE 208 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 223
TABLE 209 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 224
TABLE 210 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 226
TABLE 211 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 227
TABLE 212 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 228
TABLE 213 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 229
TABLE 214 F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2021–APRIL 2025 229
TABLE 215 CAREDX, INC.: COMPANY OVERVIEW 231
TABLE 216 CAREDX, INC.: PRODUCTS OFFERED 232
TABLE 217 CAREDX, INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–APRIL 2025 232
TABLE 218 CAREDX, INC.: DEALS, JANUARY 2022–APRIL 2025 233
TABLE 219 WERFEN: COMPANY OVERVIEW 234
TABLE 220 WERFEN: PRODUCTS OFFERED 234
TABLE 221 WERFEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 235
TABLE 222 WERFEN: DEALS, JANUARY 2022–APRIL 2025 235
TABLE 223 DIASORIN S.P.A.: COMPANY OVERVIEW 236
TABLE 224 DIASORIN S.P.A.: PRODUCTS OFFERED 237
TABLE 225 DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–APRIL 2025 237
TABLE 226 TBG BIOTECHNOLOGY CORPORATION: COMPANY OVERVIEW 238
TABLE 227 TBG BIOTECHNOLOGY CORPORATION: PRODUCTS OFFERED 238
TABLE 228 TBG BIOTECHNOLOGY CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 239
TABLE 229 TBG BIOTECHNOLOGY CORPORATION: DEALS, JANUARY 2022–APRIL 2025 239
TABLE 230 FUJIREBIO: COMPANY OVERVIEW 240
TABLE 231 FUJIREBIO: PRODUCTS OFFERED 240
TABLE 232 FUJIREBIO: DEALS, JANUARY 2022–APRIL 2025 241
TABLE 233 EUROBIO SCIENTIFIC.: COMPANY OVERVIEW 242
TABLE 234 EUROBIO SCIENTIFIC: PRODUCTS OFFERED 243
TABLE 235 EUROBIO SCIENTIFIC: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–APRIL 2025 243
TABLE 236 EUROBIO SCIENTIFIC: DEALS, JANUARY 2022–APRIL 2025 244
TABLE 237 PACBIO: COMPANY OVERVIEW 245
TABLE 238 PACBIO: PRODUCTS OFFERED 246
TABLE 239 PACBIO: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 247
TABLE 240 PACBIO: DEALS, JANUARY 2022–APRIL 2025 247
TABLE 241 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW 248
TABLE 242 BAG DIAGNOSTICS GMBH: PRODUCTS OFFERED 248
TABLE 243 CREATIVE BIOLABS: COMPANY OVERVIEW 249
TABLE 244 CREATIVE BIOLABS: PRODUCTS OFFERED 249
TABLE 245 HISTOGENETICS LLC: COMPANY OVERVIEW 250
TABLE 246 SCISCO GENETICS, INC.: COMPANY OVERVIEW 251
TABLE 247 INNO-TRAIN DIAGNOSTIK GMBH: COMPANY OVERVIEW 252
TABLE 248 BIONOBIS: COMPANY OVERVIEW 253
TABLE 249 TAKARA BIO INC.: COMPANY OVERVIEW 254
TABLE 250 KRISHGEN BIOSYSTEMS: COMPANY OVERVIEW 255
TABLE 251 SCIENCELL RESEARCH LABORATORIES, INC.: COMPANY OVERVIEW 256
TABLE 252 PROIMMUNE LTD.: COMPANY OVERVIEW 257
TABLE 253 BIOFORTUNA LIMITED: COMPANY OVERVIEW 258
TABLE 254 ALPHA BIOTECH LIMITED: COMPANY OVERVIEW 259
LIST OF FIGURES
FIGURE 1 HLA TYPING MARKET SEGMENTATION AND REGIONAL SCOPE 27
FIGURE 2 HLA TYPING MARKET: YEARS CONSIDERED 28
FIGURE 3 HLA TYPING MARKET: RESEARCH DESIGN 30
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 35
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2024 38
FIGURE 7 HLA TYPING MARKET: MARKET SIZE ESTIMATION METHODOLOGY 39
FIGURE 8 HLA TYPING MARKET: GROWTH PROJECTIONS BASED ON REVENUE IMPACT OF KEY MACRO INDICATORS 40
FIGURE 9 DATA TRIANGULATION 41
FIGURE 10 RESEARCH LIMITATIONS 43
FIGURE 11 HLA TYPING MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 44
FIGURE 12 HLA TYPING MARKET, BY PRODUCT &SERVICES, 2025 VS. 2030 (USD MILLION) 45
FIGURE 13 HLA TYPING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 45
FIGURE 14 HLA TYPING MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 46
FIGURE 15 GEOGRAPHIC SNAPSHOT OF HLA TYPING MARKET 47
FIGURE 16 GROWING NUMBER OF ORGAN TRANSPLANT PROCEDURES TO DRIVE MARKET 48
FIGURE 17 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 49
FIGURE 18 HLA TYPING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
FIGURE 19 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 57
FIGURE 20 AVERAGE SELLING PRICE OF INSTRUMENTS, 2024 (USD THOUSAND) 57
FIGURE 21 AVERAGE SELLING PRICE OF REAGENTS, 2024 (USD THOUSAND) 58
FIGURE 22 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD THOUSAND) 59
FIGURE 23 HLA TYPING MARKET: VALUE CHAIN ANALYSIS 60
FIGURE 24 HLA TYPING MARKET: SUPPLY CHAIN ANALYSIS 61
FIGURE 25 HLA TYPING MARKET: ECOSYSTEM ANALYSIS 62
FIGURE 26 INVESTMENTS AND FUNDING SCENARIO, 2019–2023 63
FIGURE 27 NUMBER OF DEALS IN MARKET, BY KEY PLAYER, 2019–2023 64
FIGURE 28 VALUE OF DEALS IN MARKET, BY KEY PLAYER, 2019–2023 (USD) 64
FIGURE 29 HLA TYPING MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024 67
FIGURE 30 HLA TYPING MARKET: IMPORT SCENARIO FOR HS CODE 3822, 2020–2024 69
FIGURE 31 HLA TYPING MARKET: EXPORT SCENARIO FOR HS CODE 3822, 2020–2024 70
FIGURE 32 HLA TYPING MARKET: PORTER’S FIVE FORCES ANALYSIS 77
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 79
FIGURE 34 KEY BUYING CRITERIA FOR END USERS 80
FIGURE 35 NORTH AMERICA: HLA TYPING MARKET SNAPSHOT 121
FIGURE 36 ASIA: HLA TYPING MARKET SNAPSHOT 146
FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN HLA TYPING MARKET, 2020–2024 184
FIGURE 38 HLA TYPING MARKET SHARE ANALYSIS, 2024 185
FIGURE 39 EV/EBITDA OF KEY VENDORS 188
FIGURE 40 5-YEAR STOCK BETA OF KEY VENDORS 188
FIGURE 41 HLA TYPING MARKET: PRODUCT/BRAND COMPARISON 189
FIGURE 42 HLA TYPING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 191
FIGURE 43 HLA TYPING MARKET: COMPANY FOOTPRINT 192
FIGURE 44 HLA TYPING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 199
FIGURE 45 BD: COMPANY SNAPSHOT (2024) 207
FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 210
FIGURE 47 ILLUMINA, INC.: COMPANY SNAPSHOT (2024) 215
FIGURE 48 QIAGEN: COMPANY SNAPSHOT (2024) 219
FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 224
FIGURE 50 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024) 228
FIGURE 51 CAREDX, INC.: COMPANY SNAPSHOT (2024) 231
FIGURE 52 DIASORIN S.P.A.: COMPANY SNAPSHOT (2024) 236
FIGURE 53 EUROBIO SCIENTIFIC: COMPANY SNAPSHOT (2024) 242
FIGURE 54 PACBIO: COMPANY SNAPSHOT (2022) 246
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11